Plus Therapeutics Soars 49.17% on Promising Brain Cancer Trial Results

Plus Therapeutics' stock surged 49.17% in pre-market trading on July 8, 2025, marking a significant rise in investor interest and confidence in the company's recent developments.

Plus Therapeutics has made substantial progress in its clinical trials, particularly with the ReSPECT-LM dose optimization trial for REYOBIQ. The company announced that initial patients have been successfully treated, showing promising results in reducing tumor size in brain cancer patients. This trial is crucial for optimizing the dosage of REYOBIQ, a radiotherapy treatment, to enhance its efficacy and safety for patients with leptomeningeal metastases.

The successful treatment of initial patients in the ReSPECT-LM trial has garnered attention from the medical community and investors alike. The positive outcomes from this trial are expected to pave the way for further advancements in the treatment of brain cancer, potentially leading to improved patient outcomes and increased market demand for REYOBIQ.

Plus Therapeutics' commitment to innovation and patient care is evident in its ongoing clinical trials and the positive results they have yielded so far. The company's focus on developing effective treatments for complex medical conditions continues to drive its growth and attract investor interest.